Insmed Inc. sell klostergang
Start price
05.09.17
/
50%
€23.52
Target price
29.12.17
€16.24
Performance (%)
20.60%
End price
29.12.17
€28.36
Summary
This prediction ended on 29.12.17 with a price of €28.36. The prediction closed with a disappointing performance of 20.60%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Insmed Inc. | -2.439% | -2.439% | 73.913% | 618.563% |
| iShares Core DAX® | -0,68 % | -4,85 % | 1,94 % | 54,33 % |
| iShares Nasdaq 100 | -0,03 % | 2,86 % | 18,90 % | 82,62 % |
| iShares Nikkei 225® | -0,54 % | -5,02 % | 28,15 % | 55,64 % |
| iShares S&P 500 | -0,21 % | 0,92 % | 13,69 % | 61,21 % |
Comments by klostergang for this prediction
In the thread Insmed Inc. diskutieren
klostergang stimmt der Sell-Einschätzung von kyron7htx zu
The open-label design of the Phase 3 trial will likely have a negative impact on secondary outcomes and may hinder the robustness of Insmed's NDA.
(Vom Mitglied beendet)